BeOne Medicines (ONC) Stock Price Target 2026

The average analyst price target for BeOne Medicines is $395.30, 5.0% below the current price. Of 16 analysts, 16 rate it Buy. Targets range from $311 to $465. The latest change came on Nov 6, 2026, when RBC Capital raised its price target on BeOne Medicines from $459 to $465 and kept an Outperform rating.

The Average Analyst Price Target for BeOne Medicines is $395.30.

Price Target Range — 8 Quarters

Analyst Consensus — 16 Analysts

2S.Buy

14Buy

Consensus RatingBuy# Analysts16Avg. Consensus PT$395.30Upside to Avg. PT-5.0%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for BeOne Medicines Stock

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 6, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$459→$465
Nov 6, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$420→$448
Nov 6, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$415→$446
Nov 6, 2026	Citizens	Reni J. Benjamin	PT Raise	Market Outperform	$405→$463
Nov 6, 2026	Wells Fargo	Yanan Zhu	PT Raise	Overweight	$400→$435
Oct 8, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$450→$459
Oct 7, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$418→$420
Oct 1, 2026	JP Morgan	Jessica Fye	PT Raise	Overweight	$425→$445
Sep 10, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$407→$415
Aug 6, 2026	TD Cowen	Yaron Werber	PT Raise	Buy	$424→$454
Aug 6, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$451→$450
Aug 6, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$416→$418
Aug 6, 2026	Guggenheim	Michael Schmitz	PT Raise	Buy	$420→$430
Aug 6, 2026	Barclays	Peter Lawson	PT Raise	Overweight	$403→$407
Aug 6, 2026	Citizens	Reni J. Benjamin	PT Raise	Market Outperform	$396→$405
Jul 23, 2026	JP Morgan	Jessica Fye	PT Raise	Overweight	$415→$425
Jul 14, 2026	Barclays	Peter Lawson	PT Cut	Overweight	$409→$403
Jul 13, 2026	Jefferies	Faisal Khurshid	Upgrade	Hold→Buy	$333→$380
Jul 7, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$436→$451
Jul 7, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$413→$416

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $465

RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and raises the price target from $459 to $465.

Benzinga Newsdesk

PRO
Truist Securities Reiterates Buy on BeOne Medicines, Raises Price Target to $448

Truist Securities analyst Gregory Renza reiterates BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $420 to $448.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on BeOne Medicines, Raises Price Target to $446

Barclays analyst Etzer Darout maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $415 to $446.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on BeOne Medicines, Raises Price Target to $463

Citizens analyst Reni J. Benjamin maintains BeOne Medicines (NASDAQ:ONC) with a Market Outperform and raises the price target from $405 to $463.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on BeOne Medicines, Raises Price Target to $435

Wells Fargo analyst Yanan Zhu maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $400 to $435.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $459

RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and raises the price target from $450 to $459.

Benzinga Newsdesk

BeOne Medicines Ltd

ニュース

パートナーシップ

ベンジンガ・グローバル

BeOne Medicines (ONC) Stock Price Target 2026

The Average Analyst Price Target for BeOne Medicines is $395.30.

Latest Upgrades and Downgrades for BeOne Medicines Stock

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $465

PRO
Truist Securities Reiterates Buy on BeOne Medicines, Raises Price Target to $448

PRO
Barclays Maintains Overweight on BeOne Medicines, Raises Price Target to $446

PRO
Citizens Maintains Market Outperform on BeOne Medicines, Raises Price Target to $463

PRO
Wells Fargo Maintains Overweight on BeOne Medicines, Raises Price Target to $435

PRO
RBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $459

People Also Watch

People Also Watch

BeOne Medicines Ltd

ニュース

パートナーシップ

ベンジンガ・グローバル

BeOne Medicines (ONC) Stock Price Target 2026

The Average Analyst Price Target for BeOne Medicines is $395.30.

Latest Upgrades and Downgrades for BeOne Medicines Stock

Analyst Ratings News

PRORBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $465

PROTruist Securities Reiterates Buy on BeOne Medicines, Raises Price Target to $448

PROBarclays Maintains Overweight on BeOne Medicines, Raises Price Target to $446

PROCitizens Maintains Market Outperform on BeOne Medicines, Raises Price Target to $463

PROWells Fargo Maintains Overweight on BeOne Medicines, Raises Price Target to $435

PRORBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $459

People Also Watch

People Also Watch

PRO
RBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $465

PRO
Truist Securities Reiterates Buy on BeOne Medicines, Raises Price Target to $448

PRO
Barclays Maintains Overweight on BeOne Medicines, Raises Price Target to $446

PRO
Citizens Maintains Market Outperform on BeOne Medicines, Raises Price Target to $463

PRO
Wells Fargo Maintains Overweight on BeOne Medicines, Raises Price Target to $435

PRO
RBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $459